PPIDT00277
Drug Information
| Name | Evolocumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB09303 |
| Type | biotech |
| Indication | Evolocumab is indicated in adult patients with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization.[L40644] It is also indicated as an adjunct to diet, alone or in combination with other hypolipidemic treatments, in adults with primary hyperlipidemia (and in pediatric patients ≥10 years old with heterozygous familial hypercholesterolemia) to reduce LDL-C.[L40644] In addition, it is indicated adjunctly to other hypolipidemic treatments in patients ≥10 years old with homozygous familiar hypercholesterolemia to reduce LDL-C.[L40644] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Parenteral; Subcutaneous |
140 MG
|
| Injection, solution | Parenteral; Subcutaneous |
420 MG
|
| Injection, solution | Subcutaneous |
140 mg
|
| Injection, solution | Subcutaneous |
140 mg/1mL
|
| Injection, solution | Subcutaneous |
420 mg
|
| Injection, solution; kit | Subcutaneous |
420 mg/3.5mL
|
| Solution | Subcutaneous |
120 mg / mL
|
| Solution | Subcutaneous |
140 mg / mL
|
| Solution | Subcutaneous |
140.000 mg
|
| Injection | Subcutaneous |
140 mg/ml
|
| Injection, solution | Subcutaneous |
140 mg/ml
|
| Injection, solution | Subcutaneous |
|
| Solution | Subcutaneous |
14000000 mg
|